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When the late Dr. John F. Fulton contracted severe pulmonary coccidioidomycosis in
January, 1942, a metastatic lesion posed the threat of further progression and fatal dissemina-
tion. The possibility that an untested and generally unavailable antibiotic, penicillin, might be of
value in Fulton's illness led his physician, Dr. John Bumstead, to appeal directly to Fulton to ob-
tain this antibiotic, but ostensibly for the benefit of another patient succumbing to hemolytic
streptococcal infection. While of no value for Fulton, penicillin was highly successful in the
treatment of his other patient and soon of a second one with staphylococcal sepsis and pneu-
monia. This penicillin, administered in March, 1942, was the first clinical trial of penicillin under
the control of the Office of Scientific Research and Development. The unique contribution of
Dr. Fulton and ofhis illness to this event is described.
A recent account by Dohrmann (1) has described the significant role played by the
late Dr. John F. Fulton in the early history of penicillin. Fulton provided much
behind-the-scenes support for his friend, Sir Howard Florey, in the initiation of
massive penicillin production in the United States during the critical early years of
World War II. It was also through Fulton's good offices that his personal physician,
Dr. John Bumstead, was able to secure the first penicillin released by the Office of
Scientific Research and Development for clinical use at a time when penicillin for all
practical purposes was still "unavailable." Dohrmann's excellent account is docu-
mented by extensive references to Fulton's diary and to other contemporary sources
of information. Dr. Fulton had no reason to suspect that his own serious illness
directly contributed to the decision to seek penicillin; as far as he was concerned, it
was in behalf of another patient of Dr. Bumstead, Mrs. Ogden Miller, who was
rapidly succumbing to streptococcal sepsis in spite ofvigorous sulfonamide therapy.
Dohrmann's account has revived many personal recollections of this first en-
counter with penicillin. On November 14, 1942, Dr. Fulton wrote to me that: "If at
any time you wish to report the case itself, I would be glad to have you do this pro-
vided you give Dr. Blake credit for having made the diagnosis! I am sure this would
meet with Dr. Bumstead's approval." This report therefore also affords me the wel-
come privilege of honoring, although not in unseemly haste, his implied invitation to
present the story ofhis serious brush with coccidioidomycosis.
Sad to relate, four of the principals involved in this incident have since died: Dr.
John F. Fulton, Sterling Professor and Chairman ofthe Department of Physiology at
the Yale Medical School, distinguished neurophysiologist, medical historian, and bib-
liophile; Dr. Francis G. Blake, Sterling Professor and Chairman, Deartment of
Medicine and Dean of the Yale Medical School; Dr. John Bumstead, Assistant
Clinical Professor of Medicine at Yale; and, across the continent, Dr. Charles E.
Smith, Professor and Chairman of Preventive Medicine and Public Health at Stan-
ford University School of Medicine at San Francisco. Dr. Smith, as the foremost au-
thority on coccidioidomycosis, was at that time serving as Special Consultant to the
Secretary of War on the program to contain this disease in the military bases operat-
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FIG. 1. Dr. Charles E. Smith examining cultures of C. immitis in his Stanford University Medical
School laboratory. Photograph by John Guttman, from an article entitled "The Mystery of the Deadly
Dust," by Myron Silverman, appearing in The Saturday Evening Post, 1949, p. 41. Reprinted with per-
mission from TheSaturday Evening Post, © 1949, The Curtis Publishing Company.
ing in the heart of the Coccidioides endemic zone. He also served as President ofthe
California State Board of Health and was soon to become Dean of the University of
California School ofPublic Health at Berkeley.
As a member of the Committee on Aviation Medicine of the National Research
Council, Dr. Fulton deplaned in California on January 9, 1942. Five days oftravel to
a variety of military installations and other institutions in the vicinity of Los Angeles
and San Diego culminated in a visit to Dr. Smith on January 13 at his laboratory in
San Francisco. This facility was dedicated to coccidioidal research, and required the
large-scale cultivation of Coccidioides immitis. Although Dr. Fulton entertained no
special zeal for coccidioidomycosis at that time, he went about the laboratory closely
inspecting the cultures as a courtesy to his gracious and enthusiastic host. Indeed, as
he subsequently wrote to Smith: "I recall sniffing one of your cultures, and I
suspected that this indiscretion on my part might be the source ofthe infection." The
hazards of infection from cultures of C. immitis have achieved considerable noto-
riety. Figure 1, which depicts Dr. Smith in his laboratory working with cultures of C.
immitis, illustrates the risks to which Dr. Fulton was exposed. Indeed, over the
years, Dr. Smith's laboratory proved to be a fertile source of infection for its
denizens, for casual visitors, and even for personnel and experimental animals on
other floors ofthe building.
Dr. Fulton dates theonset ofhis illness to January 16, when he first noted a "sticky
bronchitis." This persisted until January 27, when, as he wrote to Smith, he
developed "a massive atelectasis of the right lung a few hours before reaching New
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Haven .... I was not aware of having had a temperature or of feeling particularly
poorly between the 16th and the 27th, save for the bronchitis which was not particu-
larly disturbing."
The incubation period of primary coccidioidomycosis is well established as from
10-16 days, with extremes of 7-28 days (2). While "sniffing the culture" makes a
good story, it is difficult to reconcile with an onset 3 days later. Indeed, even if we
assume massive exposure upon arrival in California on January 9, this would still
place the incubation period at the lowest limit for acceptance. Possibly, Dr. Fulton
erred in his appraisal of the date ofonset, in which case the exposure in Dr. Smith's
laboratory would provide a very tempting probable source ofinfection.
When a critically ill Dr. Fulton entered New Haven Hospital on January 29, 1942,
the California connection was on no one's mind, although Dr. Bumstead had noted
that his illustrious patient "had been flying about the country." On January 25,
Fulton had been subjected to a drop of 35,000 feet in a compression chamber in con-
nection with his important studies in aviation physiology. A few days later, this was
followed by a spasm ofcoughing, sharp pain in the chest, and shortness ofbreath. On
admission, the fever was 104° F, the pulse at 106, and respiration at 24/min. The
initial impression was atelectasis and pneumonia ofthe right lower lobe.
X rays of the chest only contributed to the diagnostic dilemma. These were in-
terpreted as showing pneumonic infiltration ofthe entire right lung, compression ate-
lectasis of the right lower and middle lobes, right perimediastinal hydrothorax, a
markedly elevated right leaf of the diaphragm, and loculated fluid beneath the right
anterior diaphragmatic pleura. They raised the possibility of a subdiaphragmatic
origin of the illness, possibly an amoebic abscess of the liver which had ruptured into
the right hemithorax. As late as February 11, both the Physician-in-Chief, Dr.
Francis G. Blake, and The Surgeon-in-Chief, Dr. Samuel C. Harvey, concurred that
an intraabdominal basis for the elevation of the diaphragm was a likely possibility.
However, the pursuit of this lead proved unrewarding. Supradiaphragmatic alterna-
tives were also vigorously explored and included such forbidding choices as malig-
nancy, actinomycosis, tuberculosis, and unspecified pneumonia, again with no
success.
Three weeks after admission to the hospital, Dr. Blakefinally cleared the air. With
his legendary diagnostic acumen, he related the California experience to the
pulmonary lesion, the pleural effusion, the febrile course, and the leukocytosis with
eosinophilia, and on February 20 proposed San Joaquin Valley Fever, or primary
pulmonary coccidioidomycosis, as the diagnosis. To the best of my knowledge, this is
the first time that this diagnosis had been made at New Haven Hospital.' His diag-
nosis is all the more noteworthy since, in 1942, this disease was hardly within the
orbit of choices as a possible cause ofobscure pulmonary disease encountered in the
Eastern United States.
'Actually, there was a patient with primary coccidioidomycosis in New Haven Hospital in 1934, but the
diagnosis had not been made. In 1941, I received a number of strains of C. immitis from Dr. Norman
Conant of Duke University. Upon subsequent inquiry, Conant revealed that his strain #190 had originated
at New Haven Hospital. In tracking down the source ofthis culture, I found that it was recovered from the
sputum of a Yale College student who had developed pneumonia after returning from a vacation in
California. Dr. Robert Graves, Assistant Resident in Medicine, wrote an excellent description of the
fungus but did not identify it as C. immitis. This is understandable; the patient recovered, and, in 1934,
patients with coccidioidomycosis were expected to disseminate the infection and frequently die. It was not
until 1937-1938 (3,4) that the classical reports of Dickson and Gifford established the concept of primary
nondisseminating coccidioidomycosis.
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As a member of the Department of Bacteriology, diagnostic problems from time
to time gravitated to my laboratory. I had received earlier sputum specimens for
study, and both Drs. Blake and Bumstead frequently came to my laboratory to study
the preparations. Cultures for possible fungus isolation were first planted on Feb-
ruary 18 and subsequently at Dr. Blake's request on the 21st, 23d, 25th. Although
there was a heavy overgrowth with bacteria and saprophytic fungi, closer inspection
revealed telltale white cottony and stellate colonies with mycelial penetration of the
medium. These cultures were grossly and microscopically indistinguishable from cul-
tures on hand in my laboratory of known strains of C. immitis. Inoculation into mice
and guinea pigs readily yielded endosporulating spherules, thus fully confirming Dr.
Blake's clinical diagnosis.
Four days after admission to the hospital there was noted an area of erythema and
2-3 cm ofinduration on the right upper abdomen, interpreted as an early furuncle, or
possibly an insect bite. In a subsequent letter to Dr. Smith, Fulton carefully detailed
the evolution of this lesion. "This started," he wrote, "as a deep lesion in the fat and
continued to enlarge during sulfadiazine therapy which was continued for 212 weeks.
It seemed at first like an ordinary boil, but it failed to point, and it presently
developed a tough egg-shaped capsule which was about 30 mm in length and 20 mm
in width. This began to point to the surface about 10 days ago (March 2) . Dr.
Bumstead has been aspirating its content every three or four days, and usually gets1
cc ofpurulent material from its centre."
Much to everyone's dismay, my cultures of this lesion were positive for C. immitis.
Could this metastasis be a harbinger of fatal dissemination? Fulton's own close
observation of its development strongly suggested that this lesion was blood borne
and not a chance autoinoculation from the outside. I immediately communicated this
development to Smith. He replied by return mail (March 7) as follows: "As you sur-
mised, the prognostic significance of the abdominal furuncle is very grave. The only
times we have seen patients with such lesions, they have lacked the ability to focalize
the infection." More out of desperation than conviction, he recommended such
measures as the direct inoculation ofthymol into the abdominal lesion, further inten-
sive sulfonamide therapy, a trial of coccidioidin vaccine, and even artificial pneumo-
thorax. Needless to say, Smith's letter only increased the growing concern for Dr.
Fulton's chances of survival.
It was at this time that penicillin first entered the scene. In the course of some
prior conversations, Fulton had told Bumstead concerning this new antibiotic and of
the beginning efforts to produce it in the United States. Indeed, a few preliminary
reports of its extraordinary antibacterial activity had already been published in En-
gland (5). Having just viewed the positive cultures of the abdominal furuncle in my
laboratory, he raised the question of the possibility that penicillin might turn the tide
in Fulton's favor. We agreed that there was nothing to lose and perhaps much to gain
ifonly some penicillin might be procured. At the least, I might test its activity in vitro
against C. immitis. Penicillin distribution was under the most rigid control of the Na-
tional Research Council, in behalf of the Office of Scientific Research and Develop-
ment. Since Fulton had so many close ties to the National Research Council, perhaps
he himself might succeed in obtaining a sample of penicillin. Besides, Bumstead
added, he had a valid basis on which to appeal, and that was the desperate straits of
his other patient, Mrs. Ogden Miller, who was close to death from streptococcal
sepsis.
Not aware that his own possible plight was in the picture, Fulton responded with
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characteristic vigor to Bumstead's plea. As Fulton had recorded in his diary, and as
is also recounted by Dohrmann (1), Fulton first wired Dr. Norman Heatley at
Merck. Heatley was Sir Howard Florey's colleague who came to the United States
to expedite the production of penicillin. Heatley channeled the request to the
Medical Director at Merck's, who felt that he lacked the authority to release any
penicillin and referred Fulton to the eminent Dr. A. N. Richards, Chairman of the
Committee on Medical Research of the National Research Council. Not dis-
couraged, Fulton proceeded to track down Richards by the phone at his bedside.
Even Dr. Richards would not authorize the release but directed Fulton to Dr. Perrin
Long of Johns Hopkins, Chairman of the N.R.C. Committee on Chemotherapy.
Long promptly got in touch with Bumstead, and within 2 days after the appeal was
made, the first lot of penicillin reached New Haven on March 14, 1942. Although
Dohrmann, quoting Fulton's diary, states that this was the only lot of penicillin
forwarded by Merck, actually a second similar lot of5.54 g was forwarded on March
27. As a memento of the occasion, Dr. Bumstead kindly presented to me the second
empty vial and its mailing case (Fig. 2).
When Dr. Bumstead, accompanied by the Assistant Resident in Medicine, Dr.
El.
isjb. 'A
FIG. 2. The vial ofpenicillin used in the treatment ofthe "first" patient and its mailing case (Dr. Bum-
stead's name is misspelled). The full label on the vial is as follows: 5.54 grams, penicillin, (about 60 units
per mgm.), 42RD491. Caution: new drug, limited by Federal Law to investigational use. From the
Chemical Laboratories of Merck & Co., Inc., Rahway, N. J., manufacturing chemists.
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Charles Grossman, brought the vial ofpenicillin to my laboratory, we viewed it with
some concern and suspicion. It had a pungent odor, was coarse, and dark brown to
red in color; when the powder was dissolved, it resembled a solution ofiodine. We de-
cided that discretion was the better part ofvalor and passed the penicillin through an
EK Seitz (asbestos) filter pad to sterilize it. The penicillin was immediately
administered to Mrs. Ogden Miller intravenously at dosage levels of 10,000 to 20,000
units every 4 hr, day and night. Her clinical course was summarized in 1944 by Dr.
Blake (6), and actually a fuller description of her illness and response to penicillin is
found in Goodman and Gilman's book (7). Although the response of Mrs. Miller to
penicillin was prompt and dramatic, fever recurred, and, after an interruption,
therapy was resumed on March 25 and continued until April 9, primarily with the
second lot of penicillin. Enough penicillin remained to treat successfully a second
patient, a 64-year-old man with Staphylococcus aureus septicemia. As Dohrmann
reported, Mrs. Miller is alive and well today.
The penicillin was considered so precious that Dr. Heatley personallyjourneyed to
New Haven to retrieve the urine for subsequent reextraction of the antibiotic at
Merck. With his permission, and with helpful suggestions for performing the assays,
a few milliliters of penicillin were diverted for in vitro tests against the strain of C.
immitis recovered from Dr. Fulton. The results were most disappointing: Penicillin
was about 1000 times less effective against the fungus than against a susceptible
strain of Staphylococcus aureus. When apprised of the results, Heatley concluded
that "in view of the impossibility of preparing enough penicillin for even part of the
experimental needs, it might be better to postpone further work on its effects on Coc-
cidioides.7"
In spite of many desperate needs, several months followed during which penicillin
ceased to be available. Dr. Smith himself urgently appealed for it in behalf of a
moribund young soldier with disseminated coccidioidomycosis, but Perrin Long, on
the basis of our in vitro results, denied the request. It was not before June 1942 that
the National Research Council Committee on Chemotherapeutic and Other Agents
organized a program of clinical investigation of penicillin in 22 designated civilian
medical centers (8). By 1944, Dr. Blake (6), as oneofthe designated principal investi-
gators, was able to report on the clinical trial of penicillin in 200 patients at New
Haven Hospital. Mrs. Ogden Miller was his Case #1. Only after the conclusion ofthe
war did the floodgates open up.
In an editorial (9) on the history of penicillin published in 1944, Mrs. Miller is ac-
knowledged to be "the earliest patient to be studied in this country under the aus-
pices of the Office of Scientific Research and Development." Goodman and Gilman
(7) refer to this case as the "first clinical trial of penicillin in the United States." Sir
Alexander Fleming, who visited New Haven in 1945 and met Mrs. Miller, called her
"his most important patient" (1). It is only fair to point out, however, that several
pioneering studies on penicillin were reported in the United States in 1943 (10-12), so
that the experimental work on animals and on human volunteers may actually have
been at about the same time as the New Haven experience.
To return to Dr. Fulton: For almost a month, his course was significantly febrile.
The leukocyte level of22,000 on admission, with 88% polymorphonuclear leukocytes,
did not return to normal for a month, excepting for some persistent increase in
eosinophilia. The administration of a full course of sulfadiazine for 2.5 weeks had no
demonstrable effect. Dr. Smith forwarded some coccidioidin, and 0.1 ml ofa 1:100 di-
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lution was administered on February 28. The reaction was strongly positive, measur-
ing 7 by 3.5 cm, with central vesiculation, a most favorable omen. Although Fulton
felt quite well, the X ray of the chest remained stubbornly unchanging and as late as
May, 1942, showed only slight and questionable improvement. Dr. Fulton soon
regained his high spirits and dictated a stream of letters to his secretray, and the
telephone was constantly in use. His interest in coccidioidomycosis had become keen,
and he soon amassed a formidable collection of reprints on this subject. He carried
on a lively correspondence with Dr. Smith, including many aspects ofhis own illness,
not to mention a case of coccidioidomycosis in M'Bongo, a gorilla at the San Diego
Zoo.
Dr. Fulton was discharged from New Haven Hospital on March 20, 1942, with
strong admonitions from Dr. Smith to curb his activities. Soon, however, he was
chafing at the bit, and, by April 18, Smith gave him his reluctant consent to liberalize
his daily work program. It was not long before Dr. Fulton was on the road, and, on
May 5, he wrote to Smith: "As for my coccidioidal self, I am glad to report that the
three days in Baltimore (I sneaked over to Washington for one day) did not leave me
any the worse for the trip. I get out ofbreath pretty easily still, and find it convenient
to look at pretty faces until my wind returns."
In spite of the favorable clinical course and the vigorous reaction to the coc-
cidioidin skin test, the metastatic lesion continued to be a source ofconcern over the
ultimate prognosis. It is well known that coccidioidomycosis may disseminate in-
sidiously over a long period of time. Extensive studies, in which Dr. Smith himself
had been a pioneer, have established the prognostic value ofthe serological response
in coccidioidomycosis. Therefore, for a period of about 2 years, until July 5, 1944, I
forwarded 10 serum samples to Dr. Smith for complement fixation and precipitin
tests. These determinations showed a steady decline in titer, reinforcing the conclu-
sion that the infection was healing. Nevertheless, the sputum was still positive 6
months after the onset ofthe disease.
Dr. Fulton died in 1960 of causes unrelated to his serious encounter with coc-
cidioidomycosis.
One may only speculate whether Fulton's own prominence and potentially
desperate need in any way contributed to the decision to release penicillin at that
time. Letters ofinquiry came from various parts ofthe country. On March 10, Smith
wote to him: "Your illness has already achieved national prominence: a very good
friend ofours named Amos Christie who is now in Washingtonjust wrote me about it
yesterday, and the University of California and Stanford faculties are all expecting
daily bulletins."
In a study (13) of experimental infection with C. immitis, Fulton's strain was
utilized and designated as "Strain J.F.F." When Fulton spotted this report, he wrote,
in part: "I am greatly interested in your paper in the October number of the Yale
Journal on Coccidioides immitis. The fact that you were able to get something worth-
while out of my illness last winter makes me feel very much better about it.... I
hope that you will be able to spare me four or five copies so that I can send them to
my friends pointing proudly to 'Strain J.F.F.'." Perhaps he would have had a far
sounder basis for deriving some satisfaction from his severe bout of coccid-
ioidomycosis had he realized the key role his illness played in the decision to seek
penicillin at that time. As a direct consequence of his own ordeal, two other lives
were saved, and penicillin was launched on its fateful coursein American medicine.
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